Table 2.
Availability and Habits of using for Cefiderocol and Meropenem/Vaborbactam.
| Median (IQR) | |||
| Total (19/23) | 10 (1–30) | ||
| Number of patients treated M/V per Respondant | Median (IQR) | ||
| Total (19/23) | 4 (1–40) | ||
| Time of availability of Cefiderocol in your center | Median (IQR) | ||
| 8 (1–24) | |||
| Time of availability of M/V in your center | Median (IQR) | ||
| 8 (1–18) | |||
| Modality of Infusion | Cefiderocol | M/V | |
| Continuous | 2 (8.7) | 1 (4.35) | |
| >3 h | 5 (21.74) | 4 (17.39) | |
| Up to 3 h | 16 (69.57) | 18 (78.26) | |
| Cefiderocol choice (more than one response) | Empirical | Targeted | |
| Total (23/23) | 2 (8.7) | 22 (95.65) | |
| M/V choice (more than one response) | Empirical | Targeted | |
| Total (23/23) | 5 (21.74) | 21 (91.30) | |
| Cefiderocol choice (more than one response) | Clinical Failure | Microbiological failure | Both |
| Total (19/23) | 2 (8.7) | 0 (0) | 17 (73.91) |
| M/V choice (more than one response) | |||
| Total (20/23) | 3 (13.04) | 3 (13.04) | 16 (69.57) |
| M/V or Cefiderocol choice after ID consultation (more than one) | Yes | No | |
| Total (23/23) | 19 (82.61) | 4 (17.39) |
Abbreviations: M/V: meropenem/vaborbactam.